MMP9 and cardiovascular disorder: This hypothesis is supported by previously published results of a randomized controlled trial with non-diabetic patients suffering from cardiovascular diseases and elevated hs-CRP, where a significant beneficial effect of pioglitazone on hs-CRP, MMP-9 and PAI-1 could be demonstrated [21].